CClinicalTrials.gg
CompletedNCT05825352Updated May 6, 2023

PMCF Study to Evaluate Performance and Safety of "Ocular Drops Based Upon Carmellose" Used to Relieve Dry Eye Symptoms

An interventional study of Carmellose eye drops in Dry Eye, Dry Eye Disease and Kerato Conjunctivitis Sicca, sponsored by C.O.C. Farmaceutici S.r.l.. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by C.O.C. Farmaceutici S.r.l. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Dry eye disease (DED), also called keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by symptoms such as ocular discomfort and visual disturbance.

Tear Film \& Ocular Surface Society Dry Eye Workshop (TFOS DEWS) II recommends individualized management of DED based on the relative contribution of aqueous deficient and evaporative pathophysiology (to the extent that this can be determined), as well as disease severity.

First-line for treating dry eye consists of over the counter (OTC) artificial tear drops, gels, ointments, or lubricants.

Carboxymethyl cellulose (CMC) is one of the most common viscous polymers used in artificial tears to achieve prolonged residence time on the ocular surface.

For these reasons, an interventional, non-comparative, single-center Post Marketing Clinical Follow-up (PMCF) study was planned to evaluate the performance and safety of "Ocular drops based upon carmellose" used as intended to relieve dry eye symptoms.

The objectives of the PMCF study are confirmation of the performance, collection of additional safety data regarding expected adverse events and detection of potential unexpected adverse events associated with use of "Ocular drops based upon carmellose" according the Instructions for Use (IFU).

Each subject, after signing the Informed Consent Form, will enter the screening and baseline phase (the 2 visits will coincide) during which baseline procedures will be completed.

At baseline visit (V0), one of the "Ocular drops based upon carmellose" products can be dispensed to the enrolled subject, depending on Investigator clinical evaluation and decision.

The patient will perform 2 on site visits: V0 and V2/EOS. To monitor the safety, 1 phone contact is planned (V1) to check for potential adverse events and concomitant medications intake.

The first administration and the intervals at which the treatment should be repeated, to be done as per Investigator judgment and according the IFU, depend on various factors regarding the physiology of the patients (e.g. type of eye-tear film, anatomy, age), their lifestyle (e.g. use of computer, wearing of contact lenses) and their eye-surgery history (if applicable).

02

Conditions studied

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient Informed consent form (ICF) signed;
  • Male and Female Aged ≥ 18 years at the time of the signature of the ICF;
  • Patients with ocular symptoms such as burning, itching, and foreign body sensation due to environmental factors, contact lenses wearing and/or mild-severe dry eye;
  • Willing not to use other eye drops during the entire treatment period.

Exclusion criteria

Exclusion Criteria:

  • Other - different - eyes clinical conditions (e.g. glaucoma);
  • Known hypersensitivity or allergy to Investigational Product (IP) components;
  • Suspected alcohol or drug abuse;
  • Other clinically significant and uncontrolled pathologies that may interfere with study results (e.g. rheumatic diseases, diabetes);
  • Participation in another investigational study;
  • Inability to follow all study procedures, including attending all site visits, tests and examinations;
  • Mental incapacity that precludes adequate understanding or cooperation.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Eyedrops treatment arm

    Device: Carmellose eye drops

Interventions

  • DeviceCarmellose eye drops

    Ocular drops based upon carmellose

05

What researchers measure

Primary outcomes

  1. Change in Schirmer Test I: to evaluate the lubricant and protecting performance of the "Ocular drops based upon carmellose" used as Intended in subjects with mild or severe dry eye syndrome, through the Schirmer I test

    Time frame: From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2)

Secondary outcomes

  1. Change in Tear Break-up Time (TBUT): to evaluate the performance of the "Ocular drops based upon carmellose" used as Intended to ensure relief from ophthalmic stress, through the TBUT test

    Time frame: From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2)

  2. Change in Ocular Surface Disease Index (OSDI): to evaluate the eye-discomfort relieving performance of the "Ocular drops based upon carmellose", through OSDI

    Time frame: From baseline (V0 = Day 0) to 1 month (EOS/V2 = Day 30 ± 2)

  3. To evaluate the safety and tolerability of the "Ocular drops based upon carmellose", through Visual Analogue Scale (VAS) - evaluation of symptoms related to dry eye disease (burning, fatigue, discomfort, redness)

    Visual Analogue Scale: Minimum value = 0; Maximum value = 10; Higher scores mean a better outcome.

    Time frame: End of study visit (EOS/V2 = Day 30 ± 2)

  4. To evaluate the patient satisfaction through a Rensis Likert 5 points patient satisfaction scale

    Rensis Likert 5 points patient satisfaction scale: Minimum value: Very dissatisfied Maximum value: Very satisfied High score means better outcome.

    Time frame: End of study visit (EOS/V2 = Day 30 ± 2)

06

Study locations

1 site
  • Azienda Ospedaliera Policlinico Mater Domini - Università Magna Grecia di Catanzaro
    Catanzaro, CZ 88100, Italy
07

Registry details

Key details

Study ID
NCT05825352
Lead sponsor
C.O.C. Farmaceutici S.r.l.
Responsible party
Sponsor
First posted
Apr 24, 2023
Start date
Mar 24, 2022
Primary completion
Jul 29, 2022
Completion
Jul 29, 2022
Last update
May 6, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion